421 related articles for article (PubMed ID: 33923219)
21. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.
Norian LA; Kresowik TP; Rosevear HM; James BR; Rosean TR; Lightfoot AJ; Kucaba TA; Schwarz C; Weydert CJ; Henry MD; Griffith TS
PLoS One; 2012; 7(2):e31085. PubMed ID: 22312440
[TBL] [Abstract][Full Text] [Related]
22. Immune therapy for kidney cancer: a second dawn?
McDermott DF; Atkins MB
Semin Oncol; 2013 Aug; 40(4):492-8. PubMed ID: 23972713
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for renal cell carcinoma.
Bleumer I; Oosterwijk E; De Mulder P; Mulders PF
Eur Urol; 2003 Jul; 44(1):65-75. PubMed ID: 12814677
[TBL] [Abstract][Full Text] [Related]
24. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
26. Current Immunotherapies for Renal Cell Carcinoma.
Al-Marrawi MY; Holder SL
Curr Mol Pharmacol; 2016; 9(3):252-263. PubMed ID: 26177641
[TBL] [Abstract][Full Text] [Related]
27. Renal carcinoma (RC): regulation of antitumoral immune responses.
Heicappell R; Ackermann R
Prog Clin Biol Res; 1992; 378():207-16. PubMed ID: 1284503
[TBL] [Abstract][Full Text] [Related]
28. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
29. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
31. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
32. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
33. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
34. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.
Santoni M; Massari F; Amantini C; Nabissi M; Maines F; Burattini L; Berardi R; Santoni G; Montironi R; Tortora G; Cascinu S
Cancer Immunol Immunother; 2013 Dec; 62(12):1757-68. PubMed ID: 24132754
[TBL] [Abstract][Full Text] [Related]
35. Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.
Jian Y; Yang K; Sun X; Zhao J; Huang K; Aldanakh A; Xu Z; Wu H; Xu Q; Zhang L; Xu C; Yang D; Wang S
Front Immunol; 2021; 12():639636. PubMed ID: 33767709
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.
Mollica V; Santoni M; Di Nunno V; Cimadamore A; Cheng L; Lopez-Beltran A; Battelli N; Montironi R; Massari F
Curr Drug Targets; 2020; 21(14):1463-1475. PubMed ID: 32160846
[TBL] [Abstract][Full Text] [Related]
38. Role of immunotherapy in kidney cancer.
Nazzani S; Bazinet A; Karakiewicz PI
Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
[TBL] [Abstract][Full Text] [Related]
39. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
